The study evaluated the newly formatted Aspergillus-specific lateral-flow-device (LFD), and compared its performance to the original prototype "old" LFD test using 
| METHODS
This study was conducted at the Medical University of Graz, Austria in June and July 2017. We tested a convenience series of 28 BALF samples from adult patients, which were prospectively collected and tested with the old LFD (and also for GM) between November 2012 and September 2016 6, 7, 12, 13 and subsequently stored at −70°C. The samples were selected based on underlying disease (principally haematological malignancy, secondarily ICU patients), IPA status according to 2008 EORTC/MSG criteria, 14 and test result with the old LFD. All 28 samples were selected before the first sample was tested with the new LFD. Of the 14 BALF samples from patients with probable/proven IPA, 9 were positive with the old LFD (classified here as "true positives"), and 5 were negative with the old LFD (classified here as "false negatives"). Of the 14 BALF samples from patients without evidence for IPA, 9 were negative with the old LFD (classified here as "true negatives"), and 5 samples were positive with the old LFD (classified here as "false positives").
Testing with the new LFD (OLM Diagnostics, Newcastle upon Tyne, United Kingdom) was performed in our Microbiology Laboratory.
Stored BALF samples where thawed, vortexed, and immediately tested without pretreatment by applying 100 μL of BALF to the test, with results read 15 minutes later, as described previously. 
Performance of the new LFD (including 95% confidence intervals
[CI]) was compared with that of the old LFD for differentiation between probable/proven IPA and no evidence for IPA using descriptive analysis and Fishers exact test. A two-sided P-value of <.05 was considered statistically significant.
| RESULTS
A total of 28 patients (20 females, 8 males, median age 60 years, 23 underlying haematological disease, 5 ICU patients) were included in this analysis, of which 14 fulfilled the criteria for either proven (n = 3), or probable IPA (n = 11), and 14 patients had no evidence for IPA.
17/28 (61%) of patients overall, and 7/14 (50%) of patients with probable/proven IPA, were receiving mould-active antifungal prophylaxis/ therapy at the time of BALF sampling. 
++ -a
Patients with true negative results (n = 9) not displayed: all 9 had also negative results with new LFD, PCR and culture. 1/9 had a false positive BALF GM result (1.04 ODI). With regard to underlying diseases 4/9 had acute myeloid leukaemia, 2/9 had acute lymphoid leukaemia, each 1/9 had non-Hodgkin's lymphoma, multiple myeloma, and severe aplastic anaemia).
b Defined according to revised EORTC/MSG criteria (14) . AIDS, acquired immunodeficiency syndrome; BALF, bronchoalveolar lavage fluid; COPD, chronic obstructive pulmonary disease; GM, galactomannan; IPA, invasive pulmonary aspergillosis; LFD, Aspergillusspecific lateral-flow device test; n.a., not available; neg, negative; ODI, optical density index; pos, positive.
